The US FDA has unveiled draft guidance designed to assist rare disease therapy developers by providing regulatory clarity in ...
On November 3, 2026, the United States Food and Drug Administration (FDA) finalized its December 2023 draft guidance Potency Assurance for ...
The plan advances recent agency moves to accelerate “personalized” treatments by offering an approval framework for therapies ...
The FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same ...
The Healthy @Reader's Digest on MSN
Here’s what the FDA and CDC’s differing COVID vaccine guidelines mean for you and your family
Immunology experts offer clarity and explain the different verdicts. Plus, learn what you should know before heading to the pharmacy.
In a final guidance issued on Monday, the US Food and Drug Administration (FDA) laid out its expectations for cell and gene ...
The US Food and Drug Administration (FDA) on Tuesday issued draft guidance laying out its proposed regulatory approach to ...
Add Yahoo as a preferred source to see more of our stories on Google. A surgeon seated at a console performs a procedure with J&J's Ottava robotic system while several clinicians assist. Ottava ...
On October 27, 2026, the U.S. Food and Drug Administration (FDA) announced a draft guidance for industry entitled “U.S.
FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results